



Traumatic Brain Injury (TBI) Mechanisms and Novel Therapies

Guest Editor:

Dr. Maria Tikhonova

Research Institute for
Neurosciences & Medicine,
630117 Novosibirsk, Russia

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editor

Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and mortality all over the world. Four overlapping stages are distinguished in the pathogenesis of TBI: a primary lesion, the development of its consequences, secondary damage, and regeneration. Secondary lesions are associated with the combined effects of neurotransmitter excitotoxicity, electrolyte imbalance, neuroinflammation, and intracellular stress. Of the factors of secondary damage to brain cells in TBI, cerebral edema is the most frequent and dangerous. There are two major types of edema: cytotoxic edema and vasogenic edema. Cytotoxic edema is induced by hypoxia or ischemia, which leads to the upregulation of various ion channels, such as Na-K-2Cl channels, or failure of sodium-potassium pumps in the astrocytic or neuronal membrane.

This Special Issue is meant to highlight recent progress in the field. We welcome all types of articles providing new insights from experimental models and human studies about TBI mechanisms, with a focus on targets for pharmacological intervention and novel approaches to TBI treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](https://twitter.com/MDPIpharma)